Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role. The company's microbial therapy leverages naturally occurring or engineered bacteria along with a diverse community of supportive bacteria (typically more than 100 bacteria in total) to drive engraftment and durable therapeutic responses. This approach has potential in a wide range of human conditions). Initial indications pursued by the company are secondary hyperoxaluria, metabolic disorders, immune disorders, and cancer.